A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta–selective agonist in development ...